Ocata Therapeutics Inc fka OCAT

[ison929]

Compiled by another investor!!!!

I have compiled a logical series of events for the remainder calendar year 2011 for serious investors to use to gauge the companies progress in correlation to investment value.

1. Receive Patent announcement for Blastomere Program
2. Supreme Court final verdict on funding embryonic stem cell research
3. NIH definition change to include ACT’s “single-ceblastomere” hESC line
4. Announcement of new CEO, CFO
5. Awarding of grants/funds for clinical trials (from corporate slide show)
6. Begin Phase I/II clinical trial for Stargardt’s
7. EMA IND approval to begin Clinical trials for AMD in Europe
8. Begin Phase I/II clinical trial for AMD
9. Possible JV announcement for AMD/Stargardt’s and 200 other retinal diseases (off-label use of RPE cells)
10. ACT and “Roslin Cells LTD” announce new commercialization license for third party academic and commercial entities to utilize patented “single-ceblastomere” hESC Line
11. Update on first 1-3 patients undergoing clinical trials for Stargardt’s
12. Update on first 1-3 patients undergoing clinical trials for AMD
13. Announcement that company was awarded “Fast Track” or “Accelerated Approval” from FDA if treatment shows “superior effectiveness to other available treatments” and “zero side effects”: http://www.fda.gov/forconsumers/byaudien...
14. Announcement of first licensing contract(s) for patented hESC line
15. Clear remaining debt of $900,000 from balance sheet
16. Possible JV announcement for Myoblast Program
17. Receive funding to begin Phase II/clinical trial for Myoblast program
18. Receive IND approval from FDA for Hemangioblast Program
19. Announcement of successful completion of Phase I/II clinical for Stargardt’s/AMD
20. FDA approval for Phase III clinical for Stargardt’s/AMD
21. Possible announcement of Merger/Buyout negotiations (Q4 2011 – Q2 2012)
I apologize, should be 22 events (begin clinical trials in Europe for AMD). I forgot to add this event on the original post.


Conservative estimate
.02 cents per milestone: 22 events x .02 + .17 (current value) = .61


Median estimate
.03 cents per milestone: 22 events x .03 + .17 (current value) = .83


High estimate
.05 cents per milestone: 22 events x .05 + .17 (current value) = 1.27
*Any announcements regarding buyout/merger negotiations, significant JV partnerships, would skew these numbers drastically to the high side